Idorsia Ltd
Company Profile
Business description
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
Contact
Hegenheimermattweg 91
Allschwil4123
CHET: +41 588441010
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
232
Stocks News & Analysis
stocks
5 star fully franked ASX dividend payer
stocks
An undervalued stock to buy that even Warren Buffett likes
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,886.60 | 35.90 | 0.41% |
| CAC 40 | 8,101.37 | 22.89 | 0.28% |
| DAX 40 | 25,566.26 | 191.84 | 0.76% |
| Dow JONES (US) | 51,481.51 | 347.11 | -0.67% |
| FTSE 100 | 10,724.51 | 39.63 | 0.37% |
| HKSE | 24,523.57 | 118.94 | -0.48% |
| NASDAQ | 26,820.38 | 248.34 | -0.92% |
| Nikkei 225 | 65,481.27 | 396.35 | -0.60% |
| NZX 50 Index | 13,683.63 | 147.05 | -1.06% |
| S&P 500 | 7,683.69 | 59.72 | -0.77% |
| S&P/ASX 200 | 8,709.30 | 29.60 | 0.34% |
| SSE Composite Index | 3,830.45 | 6.83 | 0.18% |